Pipetting Samples

About Us

Cognosetta is a drug discovery company headquartered in Tampa, Florida. Founded in 2018, the company is focused on discovering therapeutic drugs for treating nervous system disorders.


At Cognosetta, we discover and develop ion channel and neuroreceptor modulators for therapeutic applications. Our mission is to advance innovative pharmacological solutions for tinnitus and other hearing disorders that currently lack FDA-approved medications. Cognosetta is founded on a combination of biological and clinical expertise, powerful small molecule and peptide ion channel modulators, proprietary preclinical methodology, and the determination to improve lives.


Our Leadership Team

Luisa Scott, PhD

Chief Scientific Officer and President

Dr. Scott is the Chief Scientific Officer and founder of Cognosetta. She is an expert in ion channel physiology, from altering and recording individual ion channels, to understanding how ion channels shape circuit function and behavior. She has designed biological drug discovery platforms based on high-throughput binding and phenotypic screens. As a neuroscientist, she then applied selected drug candidates to solve problems with hearing, alcohol addiction, and neurodegenerative diseases. Dr. Scott and Dr. Walton co-discovered a class of peptides that improve auditory function in hearing disorders. At Cognosetta, she is focused on fostering the validation of ion channels as targets for neurological diseases, and then discovering and developing novel therapeutic leads based on these targets.

Joseph Walton, PhD, CCC-A

Vice President, Audiology

Dr. Walton is the Vice President of Audiology and co-founder of Cognosetta. Dr. Walton is an expert in assessing hearing and auditory system function in humans and animals models. He has conducted over 20 years of research assessing peripheral and central auditory system function in mouse models of hearing disorders. He has used these models to study experimental interventions and develop objective assays of auditory function. Dr. Scott and Dr. Walton co-discovered a class of peptides that improve auditory function in mouse models of hearing disorders. Dr. Walton's broad background as an audiologist and scientist studying animal models of human disease will advance the development of drug candidates at Cognosetta that translate into effective human medications.

Michelle Bayly, PhD

Director of Medical Affairs

Dr. Bayly is the Director of Medical Affairs at Cognosetta. An accomplished neuroscientist, Dr. Bayly brings with her with over 10 years of experience in leading and managing preclinical and clinical R&D projects aimed at the identification of novel targets and therapeutic drugs for CNS, nephrology, and cardiovascular diseases.
As an experienced presenter, educator and science communicator, she's adept at making complex scientific information accessible to a wide range of audiences.   



Announcements, events and press releases

CogInc Receives Bull Ring Accelerator Funding

The University of South Florida Foundation and USF Research Foundation have awarded Cognosetta the Bull Ring Accelerator Grant to support ongoing development of our Tinnitus treatment pipeline.

June 22, 2020

CogInc Awarded AOHL's Flexi Grant

Cognosetta, Inc. received the Flexi Grant Award from the Action on Hearing Loss Foundation to continue the development of our Tinnitus treatment pipeline. We are thankful to AOHL for their work supporting individuals with hearing loss and Tinnitus.

April 8, 2020

Partnership with IonCure

We are excited to announce our partnership with IonCure (http://ioncurerx.com/), an India-based start-up. Together we will utilize AI-based drug design to expand upon our safe, ion channel-targeted drug candidates. This partnership is funded in part by the Biotechnology Research Assistance Council (https://birac.nic.in/).

February 2, 2020

SBIR Grant Awarded

Cognosetta, Inc is excited to receive a SBIR Grant from the NIH to complete dosing and safety studies for Tinnitus pipeline candidates. 

December 17, 2019

Patent granted

A patent for the small peptides discovered and developed by Cognosetta, Inc scientists has been fully granted.

February 1, 2019

Cognosetta incorporates

Cognosetta, Inc. will continue to be head-quartered in Tampa, FL. An Austin, TX office has been added. 

October 18, 2018

Stay tuned for new results!

A new study will soon be published at The Journal of Pharmacology and Experimental Therapeutics.

August, 2018

Cognosetta attends CeNeuro

CeNeuro 2018 Conference

June 25-28, 2018

Cognosetta begins

Cognosetta forms as an LLC in Tampa, FL

June 18, 2018

Science Media

Read about our scientific publications and presentations


A novel peptide restricts ethanol modulation of the BK channel in vitro and in vivo

The Journal of Pharmacology and Experimental Therapeutics, 2018


Behavioral Evidence for the Treatment of Age-Related Hearing Loss via Modulation of the BK Channel with a Custom Peptide

ARO 2018, PS286


A novel BK channel-targeted peptide suppresses sound evoked activity in the mouse inferior colliculus

Scientific Reports 2017


Implications for Presynaptic Modulation of the BK

Channel by Targeted Custom Peptides

ARO 2016, PD13


Age-Related Modulation of BK Channel

Phosphorylation and the Effects of Using Specific

Peptides That Modulate BK Function

ARO 2016, PS7


Age-Related Changes in BK Channel Composition in the Inferior Colliculus and Auditory Cortex: Modulation Via Phosphorylation and a Targeted Peptide

ARO 2015, PS506

News and Events

Cognosetta logo